Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.

Sutton G, Blessing JA, Ball H.

Gynecol Oncol. 1999 Sep;74(3):346-9.

PMID:
10479491
2.

Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group.

Gynecol Oncol. 2005 Mar;96(3):749-52.

PMID:
15721421
3.

Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.

Gallup DG, Blessing JA, Andersen W, Morgan MA; Gynecologic Oncology Group Study.

Gynecol Oncol. 2003 Apr;89(1):48-51.

PMID:
12694653
4.

Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.

Rose PG, Blessing JA, Soper JT, Barter JF.

Gynecol Oncol. 1998 Aug;70(2):267-71.

PMID:
9740703
5.
6.

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.

Curtin JP, Blessing JA, Soper JT, DeGeest K.

Gynecol Oncol. 2001 Nov;83(2):268-70.

PMID:
11606082
7.

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L.

Am J Clin Oncol. 2000 Aug;23(4):355-7.

PMID:
10955863
8.

Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

Thigpen T, Blessing JA, Yordan E, Valea F, Vaccarello L.

Gynecol Oncol. 1996 Oct;63(1):120-2.

PMID:
8898180
9.
10.

Treatment of uterine papillary serous carcinoma with paclitaxel.

Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM.

Gynecol Oncol. 2001 Jul;82(1):156-61.

PMID:
11426978
11.

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR.

Cancer. 2003 May 15;97(10):2480-6.

12.
13.

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

Lincoln S, Blessing JA, Lee RB, Rocereto TF.

Gynecol Oncol. 2003 Mar;88(3):277-81.

PMID:
12648575
14.

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.

Gynecol Oncol. 2007 Sep;106(3):596-603. Epub 2007 Jun 27.

PMID:
17597196
15.

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.

Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN.

Cancer. 2000 Dec 1;89(11):2195-201.

PMID:
11147589
16.

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.

Stathopoulos GP, Katis C, Tsavdaridis D, Dimitroulis J, Karaindros D, Stathopoulos J, Dimou E.

Cancer Chemother Pharmacol. 2006 Oct;58(4):555-60. Epub 2006 Mar 7.

PMID:
16520987
17.
18.

Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.

Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J.

Gynecol Oncol. 2002 Jun;85(3):507-10.

PMID:
12051882
19.

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG; Gynecologic Oncology Group (GOG) Study.

Gynecol Oncol. 2004 Feb;92(2):644-7.

PMID:
14766260
20.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596

Supplemental Content

Support Center